MedTrace Logo

Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

NCT00897520 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-05-19

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment.

PURPOSE: This research study is looking at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

recombinant interferon alfa

GENETIC

proteomic profiling

OTHER

immunoenzyme technique

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Monica Panelli, PhD · University of Pittsburgh

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-14
Primary Completion
2010-01-24
Completion
2010-01-24

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897520 on ClinicalTrials.gov